BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,124 filers reported holding BAXTER INTL INC in Q2 2020. The put-call ratio across all filers is 0.74 and the average weighting 0.3%.
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tavio Capital LLC | 68,405 | $5,890,000 | 7.81% |
| Iron Triangle Partners LP | 330,000 | $28,413,000 | 7.16% |
| Veritas Asset Management LLP | 8,942,428 | $769,943,000 | 5.64% |
| TSFG, LLC | 93,405 | $8,042,000 | 5.31% |
| GENERATION INVESTMENT MANAGEMENT LLP | 10,606,094 | $913,185,000 | 5.27% |
| Third Point | 4,000,000 | $344,400,000 | 4.72% |
| Avidity Partners Management LP | 800,900 | $68,957,000 | 4.42% |
| Palmer Knight Co | 62,275 | $5,362,000 | 4.17% |
| Eos Focused Equity Management, L.P. | 36,786 | $3,167,000 | 3.70% |
| Dundas Partners LLP | 196,133 | $16,887,000 | 3.69% |
| Triodos Investment Management BV | 180,100 | $15,507,000 | 3.66% |
| WHEATLAND ADVISORS INC | 9,313 | $802,000 | 3.33% |
| OBERMEYER WOOD INVESTMENT COUNSEL, LLLP | 423,938 | $36,501,000 | 3.09% |
| Progressive Investment Management Corp | 81,438 | $7,012,000 | 3.06% |
| PENSIOENFONDS RAIL & OV | 1,169,893 | $101,014,000 | 3.02% |
| Unified Trust Company, N.A. | 46,043 | $3,964,000 | 2.98% |
| CINCINNATI FINANCIAL CORP | 987,148 | $84,993,000 | 2.85% |
| NOESIS CAPITAL MANGEMENT CORP | 102,201 | $8,800,000,000 | 2.78% |
| Foyston, Gordon, & Payne Inc | 131,057 | $11,284,000 | 2.77% |
| Haverford Financial Services, Inc. | 93,304 | $8,033,000 | 2.71% |
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
External links
This page lists BAXTER INTL INC's shareholders in Q2 2020. To view BAXTER INTL INC's shareholder history, click here.